Hyloris Shareholders Unanimously Approve all Resolutions at 2021 Annual General Meeting
14,392,628 shares were represented, corresponding to 55.71% of total shares issued
Liège, Belgium – 8 June 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, announces the results from its Annual General Meeting (AGM) of Shareholders held at 2:00 pm CEST today in Liège.
Due to the coronavirus pandemic and in line with the current rules of the Belgian authorities, shareholders could not attend the meeting in person. All legal proceedings were carried out as required. Shareholders were able to exercise their rights through voting by letter ahead of the meeting or by means of a written proxy and had the opportunity to ask questions in writing ahead of the Meeting.
The Annual General Meeting unanimously adopted all agenda items, including the annual accounts for 2020, discharge of the Directors and statutory auditor, the remuneration report and the 2021 remuneration policy. In addition, the AGM approved the appointment and remuneration of Pienter Jan BV, permanently represented by Chris Buyse, to the Board of Directors.
Stijn Van Rompay, CEO of Hyloris commented: “Since our IPO in June last year, we have made significant progress across all areas of our business. We remain on track to deliver on our promise to expand our innovative pipeline of value-added reformulated and repurposed product candidates with 4 new assets this year, with the goal to have 14 approved products by 2024. We are very pleased to welcome Chris to our Board of Directors and thank all our shareholders for their continued support and engagement and look forward to seeing them in person next year.”
All documents relating to the Annual General Meeting can be consulted on the Company’s website.
About Hyloris Pharmaceuticals
Hyloris is a specialty biopharma company identifying and unlocking hidden potential in existing medications for the benefit of patients, physicians, and the healthcare systems. Hyloris applies its knowhow and technological innovations to existing pharmaceuticals and has built a broad, patented portfolio of 13 reformulated and repurposed value-added products that have the potential to offer significant advantages over currently available alternatives. Two products are currently commercialised with partners: Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a non-opioid post-operative pain treatment. The Company’s development strategy primarily focuses on the FDA’s 505(b)2 regulatory pathway, which is specifically designed for pharmaceuticals for which safety and efficacy of the molecule have already been established. This pathway can reduce the clinical burden required to bring a product to market, and significantly shorten the development timelines and reduce costs and risks. Hyloris is based in Liège, Belgium. For more information, visit www.hyloris.com and follow-us on LinkedIn.
For more information, please contact Hyloris Pharmaceuticals:
Marieke Vermeersch
VP Investor Relations and Corporate Communications
M: +32 (0)479 490 603
marieke.vermeersch@hyloris.com
Disclaimer and forward-looking statements
Hyloris means “high yield, lower risk”, which relates to the 505(b)(2) regulatory pathway for product approval on which the Issuer focuses, but in no way relates or applies to an investment in the Shares.
Certain statements in this press release are “forward-looking statements.” These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. These statements relate to future events or the Company’s future financial performance and involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control, that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Attachment
